FMP
Black Diamond Therapeutics, Inc.
BDTX
NASDAQ
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
5.07 USD
0.06 (1.18%)
About
ceo
Dr. Mark A. Velleca M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.blackdiamondtherapeutics.com
exchange
NASDAQ
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye ...
CIK
0001701541
ISIN
US09203E1055
CUSIP
09203E105
Address
One Main Street
Phone
617 252 0848
Country
US
Employee
54
IPO Date
Jan 31, 2020
Summary
CIK
0001701541
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
09203E105
ISIN
US09203E1055
Country
US
Price
5.07
Beta
2.64
Volume Avg.
647.47k
Market Cap
262.21M
Shares
-
52-Week
1.43-6.85
DCF
0.7
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.7
P/B
-
Website
https://www.blackdiamondtherapeutics.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest BDTX News
It looks like there's no news available.
